CR10289A - "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional) - Google Patents

"estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)

Info

Publication number
CR10289A
CR10289A CR10289A CR10289A CR10289A CR 10289 A CR10289 A CR 10289A CR 10289 A CR10289 A CR 10289A CR 10289 A CR10289 A CR 10289A CR 10289 A CR10289 A CR 10289A
Authority
CR
Costa Rica
Prior art keywords
stratriens
strogens
alfa
divisional
substituted
Prior art date
Application number
CR10289A
Other languages
English (en)
Inventor
Diek Kosemund
Gerd Muller
Alexander Hillisch
Karl-Heinrich Fritzemeier
Peter Muhn
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR10289A publication Critical patent/CR10289A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a nuevos compuestos como ingredientes activos farmaceuticos que presentan in vitro una mayor afinidad en preparaciones de receptores de estrogeno de prostata de rata que en preparaciones de receptores de estrogeno de utero de rata y que presentan in vivo un efecto preferencial en el ovario en comparacion con el utero, a su preparacion, a su aplicacion terapeutica y a formas farmaceuticas que contienen los nuevos compuestos.
CR10289A 2002-06-11 2008-09-16 "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional) CR10289A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Publications (1)

Publication Number Publication Date
CR10289A true CR10289A (es) 2008-11-26

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10289A CR10289A (es) 2002-06-11 2008-09-16 "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)

Country Status (29)

Country Link
EP (1) EP1517914B1 (es)
JP (1) JP4615998B2 (es)
KR (1) KR101006612B1 (es)
CN (1) CN1293090C (es)
AR (1) AR040188A1 (es)
AT (1) ATE303397T1 (es)
AU (1) AU2003242683B9 (es)
BR (1) BR0312140A (es)
CA (1) CA2486495C (es)
CR (1) CR10289A (es)
CU (1) CU23414B7 (es)
DE (2) DE10226326A1 (es)
DK (1) DK1517914T3 (es)
EA (1) EA008442B1 (es)
EC (1) ECSP055530A (es)
ES (1) ES2248770T3 (es)
HK (1) HK1081203A1 (es)
HR (1) HRP20050009B1 (es)
IL (1) IL165321A (es)
MX (1) MXPA04012491A (es)
NO (1) NO329563B1 (es)
PE (1) PE20040613A1 (es)
PL (1) PL209910B1 (es)
RS (1) RS50878B (es)
TW (1) TWI286140B (es)
UA (1) UA78062C2 (es)
UY (1) UY27844A1 (es)
WO (1) WO2003104253A2 (es)
ZA (1) ZA200500217B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
ES2307064T3 (es) * 2003-11-26 2008-11-16 Bayer Schering Pharma Aktiengesellschaft Prevencion y tratamiento de enfermedades cardiacas hipertensivas por los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,5(10)-trien-3,16alfa-diol.
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
MX2010008945A (es) * 2008-02-13 2010-09-07 Bayer Schering Pharma Ag Sistema de administracion de drogas con efecto estabilizante.
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
CA2744127A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
AU2015308987B2 (en) 2014-08-26 2021-02-18 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
DK1226155T3 (da) * 1999-11-02 2007-09-10 Bayer Schering Pharma Ag 18-nor-steroider som selektivt virksomme östrogener
CZ20023382A3 (cs) * 2000-04-12 2003-02-12 Schering Aktiengesellschaft Substituované estratrieny jako selektivně účinné estrogeny

Also Published As

Publication number Publication date
HRP20050009B1 (hr) 2013-07-31
CN1293090C (zh) 2007-01-03
DE10226326A1 (de) 2004-01-15
TWI286140B (en) 2007-09-01
HK1081203A1 (en) 2006-05-12
NO20050127L (no) 2005-03-11
EA200401544A1 (ru) 2005-06-30
RS107004A (en) 2006-10-27
ATE303397T1 (de) 2005-09-15
JP2005533053A (ja) 2005-11-04
WO2003104253A3 (de) 2004-09-16
ECSP055530A (es) 2005-03-10
AR040188A1 (es) 2005-03-16
AU2003242683A1 (en) 2003-12-22
BR0312140A (pt) 2005-04-05
JP4615998B2 (ja) 2011-01-19
UY27844A1 (es) 2003-12-31
CN1659181A (zh) 2005-08-24
CA2486495A1 (en) 2003-12-18
KR101006612B1 (ko) 2011-01-10
AU2003242683B2 (en) 2009-07-02
PL373090A1 (en) 2005-08-08
TW200407331A (en) 2004-05-16
EP1517914A2 (de) 2005-03-30
ES2248770T3 (es) 2006-03-16
KR20050009745A (ko) 2005-01-25
EA008442B1 (ru) 2007-06-29
PE20040613A1 (es) 2004-12-01
MXPA04012491A (es) 2005-06-08
EP1517914B1 (de) 2005-08-31
IL165321A (en) 2009-08-03
PL209910B1 (pl) 2011-11-30
NO329563B1 (no) 2010-11-15
DE50301116D1 (de) 2005-10-06
RS50878B (sr) 2010-08-31
CU23414B7 (es) 2009-09-08
AU2003242683B9 (en) 2009-08-27
CA2486495C (en) 2011-04-19
WO2003104253A2 (de) 2003-12-18
ZA200500217B (en) 2006-03-29
UA78062C2 (en) 2007-02-15
DK1517914T3 (da) 2006-01-16
HRP20050009A2 (en) 2005-04-30
NO20050127D0 (no) 2005-01-10

Similar Documents

Publication Publication Date Title
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
CR7022A (es) Productos esteroides hormonales y metodos para su preparacion
EA200201000A1 (ru) Гормон-заместительная терапия
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
DK0971705T3 (da) Lægemiddelformuleringer til hormonerstatningsterapi til lokal påföring på huden
WO2002017918A3 (en) Sustained release formulations for growth hormone secretagogues
DK1299108T3 (da) Parasiticidt præparat samt fremgangsmåde til fremstilling af dette præparat
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
HN1999000124A (es) Derivados de pirazol substituido.
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
ES2185124T3 (es) Composiciones de teñido de las fibras queratinicas que contienen derivados de indazoles de amina y procedimiento de teñido.
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
SG152257A1 (en) Topical preparation containing ambroxol
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
BR0208163A (pt) Terapia de reposição hormonal
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
BR0310085A (pt) Terapia de substituição de hormÈnio
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
CR6627A (es) Nuevo medicamento contraceptivo y su modo de preparacion
BR0311184A (pt) Terapia de reposição de hormÈnio
AR039228A1 (es) Terapia de reemplazo hormonal

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)